Navigation Links
Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune

ngoing phase 1 study, MT103/MEDI-538 has shown potent elimination of tumor target cells in peripheral blood, bone marrow, lymph nodes and spleen of therapy- refractory non-Hodgkins lymphoma patients.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103/MEDI-538, which is the first product candidate based on Micromet's novel BiTE(R) product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkins lymphoma. The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors, has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Micromet has established collaborations with MedImmune, Inc. for MT103/MEDI-538 and Merck Serono for adecatumumab (MT201).

Forward-Looking Statements of Micromet, Inc.

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the intended utilization of product candidates, the conduct and results of future clinical trials, plans regarding regulatory fi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
4. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:7/23/2008)...Company Focused on IND-Enabling Work with Protein ...athway of Complement System, CAMBRIDGE, Mass., Ju...day announced it has initiated a corporate growth ..., as chief executive officer and the,establishment...ker succeeds,Woodruff Emlen, M.D., a co-founder of...
(Date:7/22/2008)...- Strong efficacy results from a multi-center 293-...com , Toronto Stock Exchange Symbol: CYT, MONTRE...echnologies,Inc., the global leader in cryotherapy...unced that results previously presented from three...roduct, Arctic Front(R),were published earlier to...
(Date:7/22/2008)...Latest awards under Therapeutics Development Initi...rations to 23; next deadline January 20,2009, NE... of its mission to,speed delivery of transformativ...he Michael J. Fox Foundation for Parkinson,s Resea...ix industry research teams. The awards,were grante...
(Date:7/22/2008)...tudy Demonstrates Feasibility and Efficacy of Trea...y Liver Cancer, SAN FRANCISCO, and YONGIN-SI, Sou...San Francisco, CA and Ottawa, Ontario), and its So...day that novel findings from,a Phase I clinical tr...nstrated that the product was well-tolerated and r...
Breaking Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Psoriasis Study Showing Increased Risk of Death Underscores Need for More Research Group Says 8476 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 2MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 3Synthetech Earns National Recognition for Performance Improvement Program 2270 1Synthetech Earns National Recognition for Performance Improvement Program 2270 2Synthetech Earns National Recognition for Performance Improvement Program 2270 3Researchers hope to provide chronic fatigue syndrome answers 8470 1Researchers hope to provide chronic fatigue syndrome answers 8470 2
...History Highlighted in AACR Cancer Journal , AUSTI...Therapeutics, Inc. (NASDAQ:INGN) announced today t...nical benefit of its lead product,Advexin in a pat...,Li-Fraumeni Syndrome (LFS), a genetic disorder ch...r suppressor gene. This is the,first reported trea...
...LLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn,P...tical company,dedicated to the discovery, developm...s for cancer, central nervous system disorders,se...day announced,that Dr. John Marshall, Principal In...y,s lead cancer compound RX-0201 (Archexin),will ...
Other Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4
(Date:7/25/2008)...ne is supporting the US Department of Defense and ...olden Phoenix. Operation Golden Phoenix is a, fo...designed to assist, federal, state and local agenc...enarios. Dataline is providing a vital, ad-hoc, se...dical use during the exercise., NORFOLK, Va., Jul...
(Date:7/25/2008)...HAUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Pha...rmaceutical company, today announced that it,has l... antiarrhythmic,indicated for the treatment and pr...illation and hemodynamically unstable ventricular,...gular heart beat.,Sagent,s amiodarone HCl injectio...
(Date:7/25/2008)...finds fluid back-up in esophagus can cause immune ...thDay News) -- The first evidence linking gastroes... discovered by Duke University Medical Center rese...tions was first noted in the 1970s, and since then... percent of asthma patients also experience GERD s...
(Date:7/25/2008)... Whether you are an Olympian, P...ior, there are Five Things You Need to Know about ...I.S.C. Spine and Sports Center , ...08 -- America,s premier athletes are heading to Be...oning and sacrifice in the hopes of capturing an O...
Breaking Medicine News(10 mins):Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
... Industries Ltd today said it has acquired a signi...ary of US-based indigene Pharma Inc// , for an und...iopharmaceuticals, has been in the business of bot... healthcare products. Commenting on the strategic...
...discovery may help treat stroke-affected humans Ne...s recover after a stroke by stimulating a protein/...pes about the possibility of repairing the human b...h as stroke or spinal-cord damages. The findings ...
...ciate Health Minister Jim Anderton said that the G... people in all age groups//. New Zealand has a ve...given to bring down youth suicide rates. According...ms in 2003 were aged 25 or older. Suicide rates am...
...archers have concluded that earlier a deaf child r...r spoken language skills, sentence formation and u...deaf but used cochlear implants, able to hear part...he right time to make use of it. In contrast, a c...
Other Medicine News:Health News:Earlier the Cochlear Implants Used Better the Speech 2Health News:Earlier the Cochlear Implants Used Better the Speech 3
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: